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The difference between high-LET and low-LET radiation is quantified by
a measure called relative biological effectiveness (RBE). RBE is defined
as the ratio of the dose of a reference radiation to that of a test radiation to
achieve the same effect level, and thus, is described either as an iso-effect
or dose-to-dose ratio. A single dose point is not sufficient to calculate an
RBE value; therefore, studies with only one dose point usually calculate an
effect-to-effect ratio [1-3]. While not formally used in radiation protection,
these iso-dose values may still be informative. Shuryak, et al 2017 [4]
investigated the use of an iso-dose metric termed “radiation effects ratio”
(RER) and used both RBE and RER to estimate high-LET risks.
To apply RBE or RER to risk prediction, the selected metric must be
uniquely defined. That is, the calculated value must be consistent within a
model given a constant set of constraints and assumptions, regardless of
how effects are defined using statistical transformations from raw endpoint
data. We first test the RBE and the RER to determine whether they are
uniquely defined using transformations applied to raw data. Then, we test
whether both metrics can predict heavy ion response data after simulated
effect size scaling between human populations or when converting animal
to human endpoints.
Models for Harderian gland tumor induction after gamma ray and heavy ion
exposures were generated using mouse data from Chang, et al 2016 [5].
CB6F1/Hsd mice were irradiated acutely with ≤0.5 Gy of 260 MeV/u 28Si or 137Cs
gamma rays. After 16 months, the number of animals with Harderian gland tumors
(T) and the total number of animals alive at the end of this period (N) were recorded.
Only animals alive at the end of the 16-month period were included in the analysis.
Methods: Study 1
Methods: Study 2
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Table 1:  Calculating E(D) for Each Combination of Link Function and 
Effect Scale 
Harderian gland tumor count (T) per number at risk (N) was analyzed as a
binomial parameter. Two transformations of this binomial parameter were applied
using the identity and log-complement link functions of generalized linear models
(GLMs). To visualize the results from each GLM, we considered two different “effect
scales” for the y-axis: tumor prevalence (T/N) and log tumor-free survival prevalence
(ln[1-T/N]). The identity link has a linear relationship with the tumor prevalence effect
scale, and the log-complement link has a linear relationship with the log tumor-free
survival prevalence scale. Control data was analyzed using each link function prior
to radiation modeling. Baseline tumor prevalence (cid) was estimated using the
identity link function, and baseline log tumor-free survival prevalence (clogc) was
estimated using the log-complement link function. Note that cid and clogc are
transformations of one another: cid = 1-exp(clogc)
For each link function, Si and gamma ray data were analyzed in one GLM with
radiation type as a categorical variable. The estimate for the appropriate control (i.e.,
cid or clogc) was modeled as a fixed parameter to force the y-intercept to be the
observed background number of tumors. For both the identity and log-complement
link functions, estimates of the linear slope with respect to dose were defined for
each ion (αI,id and αI,logc, respectively) and for gamma rays (αγ,id and αγ,logc,
respectively). Table 1 shows the relationship between link functions and effect scales
with regard to effect estimates as a function of dose, E(D).
Since all our models can be simplified to a linear equation, the RBE is:
Equation 1:  𝑅𝐵𝐸 =
𝛼𝐼
𝛼𝛾
The equation defined in Shuryak, et al 2017 [4] is used to calculate the RER:
Equation 2:  𝑅𝐸𝑅 =
𝐸𝐼(𝐷)−𝐸𝐼(0)
𝐸𝛾(𝐷) − 𝐸𝛾(0)
The equations from Table 1 can be placed in the RER formula to calculate the 
resulting RER values when different link functions and effect scales are selected.
In this study, simulations were run to test the ability of both the RBE and the RER 
to predict “known” heavy ion effects. The linear equations corresponding to gamma 
rays and Si from the Chang, et al 2016 [5] data are:
Equation 3:  𝐸𝛾(𝐷) = 4.8 + 6.8𝐷
Equation 4:  𝐸𝑆𝑖(𝐷) = 4.8 + 74.4𝐷
where E refers to the effect at any given dose, D.
These models were used to predict effects in mice at each gamma ray and Si
dose, respectively. For each predicted gamma ray effect, a corresponding Si dose
(i.e., the dose of Si required to produce the same gamma ray effect) was back-
calculated. The abilities of calculated RBE and RER values from Chang, et al 2016
[5] to predict the original heavy ion data were verified, where original heavy ion data
refers to that used to calculate the RBE and RER values. Two data centering
schema were used: background Harderian gland tumor level (4.8) and zero [4].
Scale changes are expected when translating effects from mice to humans and
between human populations. The data was transformed by subtracting the arbitrary
number two from both the gamma ray and Si effects to imitate the change in scale
from mouse tumor prevalence to human cancer incidence [5-7]. The response was
forced to be zero if the transformation created negative values. The data were also
scaled in the opposite direction by adding the arbitrary number fifteen to both the
gamma ray and Si effects to model potential human-to-human scaling effects for
different disease endpoints, assuming certain populations have higher incidences of
certain cancers [8,9]. Additive scaling was used to model both additive risk changes
and supra- and sub-multiplicative risk changes, which could require both an additive
and a multiplicative component.
As both models were linear, RBE was equivalent at all effect values in
both the background-centered and zero-centered schema. In the
background-centered schema, the RER steadily increased over dose. In
the zero-centered schema, the RER was equivalent at all doses and equal
to the RBE. Both the back-calculated Si doses from the RBE and the
back-calculated Si effects from the RER mapped appropriately to the
original doses and effects in both centering schema (not shown).
When the RBE and RER from both the background- and zero-centered
schema were applied to the simulated mouse-to-human scaled gamma
ray data, the RBE correctly predicted while the RER underpredicted the Si
response (Fig. 3).
When the
gamma ray and
Si data were
scaled upwards
from their
original values
(human-to-
human scaling
simulation), the
RBE correctly
predicted the Si
response in
Fig. 3:  (A) Background-centered and (B) zero-centered 
gamma and Si data with RBE and RER effect estimations 
for potential mouse-to-human predictions
Fig. 4:  (A) Background-centered and (B) zero-centered 
gamma and Si data with RBE and RER effect estimations 
for potential human-to-human predictions
Results:  Study 1 Results:  Study 2
Fig. 1: (A) Harderian gland tumor prevalence and (B) tumor free survival
prevalence per 100 mice after exposure to a range of gamma-ray doses
and single doses of Si irradiation. Bars represent 95% Wald confidence
intervals for the binomial variables.
A. B.
Fig. 2: Estimated RER from fitted parameters
for (A) the identity function GLM link and (B)
the log-complement function GLM link as a
function of dose (Gy)
both the background- and zero-centered schema. The RER, on the other
hand, overpredicted the Si effect (Fig. 4).
The background tumor prevalence was 4.8 per 100 mice. The
background log tumor-free survival prevalence was -0.05. The link
functions fit the data equally well based on Akaike’s information criterion.
Therefore, RBE is uniquely
defined within models.
Fig. 2 illustrates the
RER values estimated from
the identity and the log-
complement link functions.
The RER and RBE are
equivalent when both of
these models are linear.
However, RER estimates
change depending on
choice of tumor prevalence
or log tumor-free survival
prevalence effect scale.
Thus, RER is not uniquely
defined.
The RBE values estimated from the identity link and log-complement
link are 11.0 (3.2, 17.3) and 11.7 (4.5, 18.9), respectively. The 95%
confidence intervals overlap; these differences are not significant.
Differences are not seen within link functions over the two effect scales.
 RBE was uniquely defined while RER was not
 RBE successfully predicted the scaled Si effects while RER did not
 In this scenario, the dose scale is constant while the effect scale is
variable [8,9]
• RBE depends only on the exposure, while RER depends on the chosen
effect
• The exposure, absorbed dose, is measured identically regardless of the
radiation circumstances and target
• In this context, RBE is predictive of the heavy ion effects while RER is not
 If the effect scale was constant while the dose scale was variable, RER 
would be uniquely defined while RBE would not be uniquely defined
• If multiple distinct exposure types were compared in two similar groups of 
subjects, the effect scale between the two groups would be constant, 
while the dose scales would be variable
 Given only a single dose-point, an RER could be calculated and 
applied to later data as an RBE if (and only if) linearity is assumed for 
both the gamma ray and heavy ion dose responses
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